ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation statusSandro Pignata, Andrew R. Clamp, Amit M. Oza et al.|Gynecologic Oncology|2021Cited by 5
Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.Sandro Pignata, Andrew R. Clamp, Radosław Mądry et al.|Journal of Clinical Oncology|2022Cited by 5